Human High sensitive Interferon gamma ELISA Kit

Brucellosis is the most common bacterial zoonotic infection. This pathogen may survive and sustain in host. The aim of this study is to define relationship between long noncoding (lnc) RNA-IFNG-AS1 and interferon gamma (IFN-gamma) in different groups of patients with brucellosis compared to control group. In this study, associations of lncRNA IFNG-AS1 expression with secretion of IFN-gamma level in Sixty patients with brucellosis, which were divided into 3 groups (acute, chronic and relapse groups), as a case group were compared with 20 subjects with negative serological tests and brucellosis clinical manifestation as a control group. In this regard, RNA were extracted from isolated peripheral blood mononuclear cells (PBMCs). LncRNA IFNG-AS1, T-box transcription factor (T-bet) and IFN-gamma expressions were detected using quantitative polymerase chain reaction (qPCR). Serum level IFN-gamma was assessed using enzyme linked immunosorbent assay (ELISA). The results showed that expression level of LncRNA IFNG-AS1, T-bet and IFN-gamma increased significantly in all patient groups in compared to healthy subjects (P<0.0001, P<0.01, P<0.001). However, there was no significant difference in T-bet expression between chronic and healthy groups (P=0.98). Additionally, further analysis revealed that the serum level of IFN-gamma in acute and relapsed groups were higher than control group (P<0.0001, P<0.001). The effective role of IFNG-AS1 in many protective actions, including enhancing the expression of INF-gamma in the immune response of brucellosis patients, revealed new potential marker, LncRNA IFNG-AS1 in screening, diagnosis or treatment of brucellosis.

Molecular diagnosis of rejection is emerging in kidney, heart, and lung transplant biopsies and could offer insights for liver transplant biopsies. We measured gene expression by microarrays in 235 liver transplant biopsies from 10 centers. Unsupervised archetypal analysis based on expression of previously annotated rejection-related transcripts identified 4 groups: normal "R1(normal)" (N = 129), T cell-mediated rejection (TCMR) "R2(TCMR)" (N = 37), early injury "R3(injury)" (N = 61), and fibrosis "R4(late)" (N = 8). Groups differed in median time posttransplant, for example, R3(injury)99 days vs R4(late)3117 days. R2(TCMR)biopsies expressed typical TCMR-related transcripts, for example, intense IFNG-induced effects. R3(injury)displayed increased expression of parenchymal injury transcripts (eg, hypoxia-inducible factor EGLN1). R4(late)biopsies showed immunoglobulin transcripts and injury-related transcripts. R2(TCMR)correlated with histologic rejection although with many discrepancies, and R4(late)with fibrosis. R2(TCMR), R3(injury), and R4(late)correlated with liver function abnormalities. Supervised classifiers trained on histologic rejection showed less agreement with histology than unsupervised R2(TCMR)scores. No confirmed cases of clinical antibody-mediated rejection (ABMR) were present in the population, and strategies that previously revealed ABMR in kidney and heart transplants failed to reveal a liver ABMR phenotype. In conclusion, molecular analysis of liver transplant biopsies detects rejection, has the potential to resolve ambiguities, and could assist with immunosuppressive management.